Yarrow Bioscience, Inc.
No SEC Form 4 filings for $YARW in the last 30 days.
See all $YARW insider activity →Yarrow Bioscience, Inc. (YARW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as the representative
Yarrow Bioscience Inc (YARW) shares fell 7% after pricing a $150 million public offering of 5.8 million shares at $26 each. The stock is currently trading at $26.55, down 6.65% from the previous close of $28.44 on the Nasdaq.
Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning YARW (Yarrow Bioscience, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent YARW coverage spans financial news, corporate actions and earnings.
The capital raise provides significant cash for R&D and may dilute existing shareholders, likely supporting short‑term price volatility.
The pricing dilutes existing shareholders and triggers a near-term price decline.
New trial launch and Fast Track designation boost outlook.
Yarrow Bioscience, Inc. disclosed in a Schedule 13G/A that Logos Global Management LP and related funds report beneficial ownership of 286,308 shares, or 10.7% of the common stock class, based on 2,669,788 shares outstanding as of July 29, 2026. The group also cites prefunded warrants for 2,201,030 shares excluded under a 9.99% limit.
M&A plus new funding can extend runway and shift development priorities, but integration and dilution overhang remain key risks.
AlphAI scores every news story that mentions YARW with an AI model for sentiment and relevance, and aggregates insider trades from Yarrow Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Yarrow Bioscience, Inc. (YARW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as the representative
1 min readYarrow Bioscience Inc (YARW) shares fell 7% after pricing a $150 million public offering of 5.8 million shares at $26 each. The stock is currently trading at $26.55, down 6.65% from the previous close of $28.44 on the Nasdaq.
1 min readPicard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.
3 min readYarrow Bioscience, Inc. disclosed in a Schedule 13G/A that Logos Global Management LP and related funds report beneficial ownership of 286,308 shares, or 10.7% of the common stock class, based on 2,669,788 shares outstanding as of July 29, 2026. The group also cites prefunded warrants for 2,201,030 shares excluded under a 9.99% limit.
2 min readBiotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
7 min readYarrow Bioscience (VYNE) holder swaps 133K shares for warrants Rhea-AI Filing Summary Yarrow Bioscience, Inc. reports that an affiliated RTW Entity managed by RTW Fund Group GP, LLC exchanged 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares on July 29, 2026.
2 min readYarrow Bioscience, Inc. (VYNE) holders report 8,816,429 pre-funded warrants Rhea-AI Filing Summary RTW Fund Group GP, LLC and Roderick Wong, M.D., reported as ten percent owners of Yarrow Bioscience, Inc., disclose indirect holdings received in a July 27, 2026 merger: 399,597 shares of common stock and pre-funded warrants exercisable at $0.0001 for 8,816,429 shares, subject to a 9.99% beneficial ownership cap.
4 min readRTW Biotech Opportunities said Yarrow Bioscience completed its merger with VYNE Therapeutics, alongside about $200m in private financings led by RTW. The combined company began Nasdaq trading as Yarrow Bioscience under ticker YARW. YB-101 received FDA Fast Track; Phase 2a data are expected in 2H 2027.
3 min readYarrow Bioscience, Inc. (VYNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-3.5 6 tm2620687d3_ex3-5.htm EXHIBIT 3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF YARROW BIOSCIENCE, INC. (a Delaware corporation) Article I CORPORATE OFFICES Section 1.1 Registered Office . The registered office of Yarrow Bioscience, Inc., a Delaware corporation (the “ Corpo
6 min readVYNE Therapeutics said it distributed a special cash dividend to holders of record July 22, 2026, paid July 23, subject to Nasdaq due bill procedures, ahead of a planned 1-for-50 reverse split effective July 24 and split-adjusted trading July 27. VYNE expects merger closing with Yarrow Bioscience early in the week of July 27, with the combined company trading as YARW. VYNE closed at $0.9234.
2 min read
